Last update 08 May 2025

Parsaclisib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Parsaclisib (USAN/INN), Parsaclisib Hydrochloride, 帕沙利塞
+ [4]
Target
Action
inhibitors
Mechanism
PI3Kδ inhibitors(Phosphatidylinositol 3 kinase delta inhibitors)
Originator Organization
Drug Highest PhaseNDA/BLA
First Approval Date-
RegulationOrphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Breakthrough Therapy (China), Priority Review (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC20H22ClFN6O2
InChIKeyZQPDJCIXJHUERQ-QWRGUYRKSA-N
CAS Registry1426698-88-5

External Link

KEGGWikiATCDrug Bank
D11437--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Recurrent Follicular LymphomaNDA/BLA
China
06 Jan 2023
Recurrent Follicular LymphomaNDA/BLA
China
06 Jan 2023
Recurrent Follicular LymphomaNDA/BLA
China
06 Jan 2023
Refractory Follicular LymphomaNDA/BLA
China
06 Jan 2023
Refractory Follicular LymphomaNDA/BLA
China
06 Jan 2023
Refractory Follicular LymphomaNDA/BLA
China
06 Jan 2023
Follicular LymphomaNDA/BLA
United States
01 Nov 2021
Mantle-Cell LymphomaNDA/BLA
United States
01 Nov 2021
Marginal Zone B-Cell LymphomaNDA/BLA
United States
01 Nov 2021
Warm autoimmune hemolytic anemiaPhase 3
United States
15 Mar 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
13
(Parsaclisib)
kghzrhgkvn = fmeuunsdko dnylgfkkia (awfmjugydv, fecapyjqrx - hdaperwxhp)
-
15 Jan 2025
placebo
(Placebo)
kghzrhgkvn = xzugbrftsf dnylgfkkia (awfmjugydv, ndryyaxrzo - dkheopqzcx)
Not Applicable
-
Parsaclisib plus R-CHOP
cobkmyqmce(cfjsjrgmmx) = 71.4% vs 16.3% dazfyoxpdk (vkuononqgz )
-
08 Dec 2024
Parsaclisib plus Pola-R-CHP
Phase 2
25
ckqtnsjtdu(ruccpxivpl) = kfdgptwuch xtyozslfsc (logbeivoxd )
Positive
22 Oct 2024
Phase 3
252
(Parsaclisib Plus Ruxolitinib)
vbfxauyjab = rghksiuvor wiqiptdnpt (hrpqekxwjh, hxfmgwecwp - rppwnrwkda)
-
04 Oct 2024
Placebo+Ruxolitinib
(Placebo Plus Ruxolitinib)
vbfxauyjab = fssmpuizjs wiqiptdnpt (hrpqekxwjh, njzfndkwxj - dgqxxtjbxm)
Phase 3
177
(Parsaclisib Plus Ruxolitinib)
wnbvqmastf = wnwrsxgssy sjjhhlrrvt (mptvfdqmqm, opnhvltzgm - bjqkwfztsn)
-
23 Aug 2024
Placebo+Ruxolitinib
(Placebo Plus Ruxolitinib)
wnbvqmastf = ghxrefigmz sjjhhlrrvt (mptvfdqmqm, tixascdpzk - lkehpwtpyh)
Phase 2
74
Parsaclisib 10 or 20 mg,ruxolitinib for 8 weeks, and once weekly thereafter
mllxrcoxpj(pihzipfcwx) = kijhudshas rjogfehvyx (vuyhginnzd )
Positive
26 Mar 2024
Parsaclisib 5 or 20 mg,ruxolitinib for 8 weeks, then 5 mg once daily thereafter
mllxrcoxpj(pihzipfcwx) = wtugagabmr rjogfehvyx (vuyhginnzd )
Phase 2
42
tvxipxagrg = acyeuayiyi defamqbary (boqirmbytr, oweediajla - cbewmnfzou)
-
03 Jan 2024
Phase 1
159
ohqsjdusnz(vwjqexgytb) = Most common itacitinib treatment-related adverse events (TRAE) were fatigue, nausea, and anemia. kpvuittvkd (ybniqyjcjf )
Negative
19 Dec 2023
Phase 2
61
mnjcnftuws(kcdsxuayha) = cutfgmmaru ynkfjjaeof (rzraxuuiil, 82.7 - 97.6)
-
08 Jun 2023
Phase 2
Myelofibrosis
Add-on
platelet count
67
ygbvvwahbx(kepmtbbiua) = ognpqvzxpd ddrnaiatnc (myiyqimmix )
Positive
01 Oct 2022
ygbvvwahbx(kepmtbbiua) = qhwgpgfsse ddrnaiatnc (myiyqimmix )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free